SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Aurora Biosciences (ABSC)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: sasha4477 who wrote (234)12/10/1999 2:07:00 PM
From: biowa  Read Replies (1) of 359
 
Sasha,

<<if I understand correctly this is a second stage technology used to narrow down or identify the underlying infrastructure to be attacked by the new drug through a screening process>>

First stage is identifying a potential target in a disease-related pathway (whether that target is a gene, an RNA transcript, an enzyme, etc.). Second stage is validating that target as impacting the pathway (you'd really like to link it all the way up to the human disease state); by the way this is also one step cited as a bottleneck, and there are many companies (alot still in their infancy) working on "high-throughput target validation." Third stage is what ABSC does (as I understand it) which is using those validated targets to screen a library of candidate molecules to identify promising "leads". Following that is lead optimization and several pre-clinical steps, and then maybe, just maybe you file an IND and go into human clinicals. Highly simplified, but hope this helps.

biowa
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News